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Tetralogy of FallotTetralogy of Fallot (TOF) results in chronic progressive right ventricular (RV) pressure overload
and shunt hypoxemia.We investigated the global changes in the proteomeof RV among infant
patients with and without TOF to gain an insight into early RV remodeling. One hundred and
thirty-six differentially expressed proteins were identified using label-free LC–ESI-MS/MS
analysis. Western blot results revealed that the expression of 6-phosphofructo-2-kinase/
fructose-2,6-biphosphatase 2 (PFKFB2) increased significantly in TOF patients; and levels of
lysocardiolipin acyltransferase 1 (LCLAT1), lumican (LUM), and versican (VCAN) decreased
significantly. QRT-PCR analysis showed that levels of PFKFB2mRNAweremarkedly increased,
but thoseof LCLAT1andLUMwere significantly decreased.VCANmRNAshowednosignificant
change in response to pathophysiology of TOF. The results of immunohistochemical staining
were similar to those ofWestern blot analysis. Results of the proteomic analysis indicated that
the level of glycolysis-related proteins had increased and levels of lipid-metabolism-related
proteins had decreased. ECM proteins were found to be more down-regulated in TOF in the
present study than in previous reports. Taken together, our findingsmay provide clues to both
themetabolic inflexibility and ECM remodeling during the early RV remodeling, which occur in
response to chronic hypoxia and long-term pressure overload in TOF patients.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY license.Right ventricle
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Congenital heart defects (CHDs), which occur at a rate of ap-
proximately 8 per 1000 live births, are the most common life-
threatening birth defects [1,2]. Advanced diagnostic and treat-
ment services provided by prenatal screening programs
dramatically improve survival and quality of life. This has
allowed the number of patients in China with very se-
rious illnesses to increase steadily over the past few decades.
Cardiac morphological defects, inducing malhemodynamic
overload and shunt hypoxemia, are the two main risk factors
formanyof thesepatients. They interferewith the functionof the
ventricles and cause cardiac hypertrophy and remodeling [3,4].
Tetralogy of Fallot (TOF) is the most common cyanotic
complex CHD. The four classic features that characterize TOF
are ventricular septal defect (VSD), over-riding of the aorta,
right ventricular outflow tract obstruction (RVOTO), and right
ventricular hypertrophy [5]. Anatomic defects cause function-
al abnormalities in TOF patients. Before TOF surgical repair,
the main pathophysiological abnormalities are long-term
right ventricle (RV) pressure overload and chronic hypoxia. In
TOF, significant RVOTO typically includes infundibular hyper-
trophy and abnormal muscle bundles, which both induce
pressure overload, progressive RV hypertrophy, and decreases
in pulmonary blood flow. The VSD is almost always large and
non-restrictive in TOF. The direction and magnitude of flow
through the defect depend on the severity of the RVOTO. If
RVOTO is severe, a large right-to-left shunt with low pulmo-
nary blood flow and severe cyanosis are present. However,
most patients have adequate pulmonary blood flow at birth
but develop increasing cyanosis during the first few weeks or
months of life [6]. The treatment of TOF patients requires
surgical intervention, and primary repair in the first year of life
is the most common strategy [7].
Currently, with the development of surgical strategies for
CHD, the pathophysiology of CHD has attracted much more
attention, and the importance of RV pathophysiology has also
increased.Although therearemanypublishedstudies addressing
RV dysfunction, RV remodeling studies have been limited tothemiddle and late stages of this condition, and the early stage
has been neglected. Exploration of the molecular mechanisms
that underlie the pathophysiological changes in early stages
among human CHD pediatric patients remains a challenge.
The proteomic approach is a powerful technique used to
analyze the complexity of proteins, and elucidate their biolog-
ical roles, including biochemical processes, structure, and
function. Label-free mass spectrometric techniques combined
with spectral counting and statistical comparative analysis
have yielded data that show considerable reproducibility and
utility as a semi-quantitative measure of differential protein
abundance [8]. However, proteomic analyses of RV remodeling
in human infant TOF are limited.
In the present study, we attempted to study the RV re-
modeling among infant TOF patients using a label-free
quantitative proteomic approach. The purpose was to identify
proteins associated with chronic hypoxia, long-term RV
pressure overload, and maladaptive processes that occur in
response to early cardiac remodeling.2. Materials and methods
2.1. Study population
We recruited 20 CHD patients from the Shanghai Children's
Medical Center. The study protocol was approved by the
Institutional Research Ethics Committee of Shanghai
Children's Medical Center. Informed written consent was
obtained from all patients and guardians. Myocardial tissue
was collected from the Heart Center of Shanghai Children's
Medical Center between November 2011 and March 2012. A
total of 10 unrelated patients with sporadic classic TOF were
identified, and 10 non-TOF patients lacking deviation of the
outlet septum were recruited as controls from among patients
undergoing any other type of cardiac surgery (artery valve
surgery, coronary artery fistulae). All patients underwent a com-
plete physical examination. Clinical data, including medical
records, electrocardiograms, echocardiography, and cardiac
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University Pediatric Heart Failure Index (NYU PHFI) andmodified
Ross score were used to evaluate heart function [9]. The RV
myocardial tissue specimens were obtained from surgical
resection of the right ventricular outflow myocardial tissue to
relieve the obstruction. This also confirmed the presence of the
TOF phenotype and the absence of any other heart malforma-
tion, such as patent ductus arteriosus (PDA) or atrial septal defect
(ASD). In general, the fragments of cardiacmuscle obtained here
were approximately 20 mg in size. The harvested tissue samples
were divided into two equal pieces after the bloodstains were
removed with normal sterile saline. All samples were frozen in
liquid nitrogen immediately after excision and stored at −80 °C.
2.2. Sample preparation
We use filter-aided sample preparation (FASP) to extract
protein from the myocardium, as previously described [10].
All samples were analyzed individually and were not pooled
at any point. In brief, 10 mg wet tissue was mixed with 200 μl
of 8 ml urea in Microcon devices YM-10 (Millipore). The
mixtures were centrifuged at 14,000 g at 20 °C for 40 min. All
the following centrifugation steps were performed using
the same conditions. The concentrates were diluted with
200 μl of 8 M urea in 0.1 M Tris–HCl, pH 8.5 and the device was
centrifuged. Subsequently, 100 μl of 0.05 M iodoacetamide
in 8 M urea in 0.1 M Tris–HCl, pH 8.5 was added to the
concentrate and then centrifuged. The resulting concentrate
was diluted with 100 μl 8 M urea in 0.1 M Tris–HCl, pH 7.9 and
concentrated again. This step was repeated 2 times, and the
concentrate was subjected to proteolytic digestion. The prod-
ucts of digestion were collected by centrifugation, and the
filter device was rinsed with 50 μl 0.5 M NaCl and centrifuged.
The combined filtrates were desalted on anMILI-SPE Extraction
disk cartridge; 7 mm per 3 ml (Millipore). The protein con-
centrationwasdetectedbymeasuring tryptophan fluorescence.
Briefly, 1 μl of sample or tryptophan standard (100 ng/μl) was
added to 3 ml of 8 M urea buffer (8 M urea, 20 mM Tris–HCl,
pH = 7.6). Fluorescence was excited at 295 nm andmeasured at
350 nm. The slits were set at 10 nm.
2.3. Isoelectric focusing of peptides and mass spectrometric
analysis
We separated 0.05 mg of peptides into 12 fractions on the 3100
Offgel Fractionator (Agilent Technologies) as described previ-
ously. The immobilized pH gradient strips (IPG strips) from GE
Healthcare (Immobiline DryStrip pH 3–10, 13 cm) were rehy-
drated with 20 μl per well of isoelectric focusing buffer
containing 5% glycerol and 50-fold diluted IPG buffer pH 3–10
(GE Healthcare) for 20 min. Peptides were dissolved in 1.68 ml of
isoelectric focusing buffer and 0.14 ml of the solutionwas loaded
into to each well. Mineral oil was added to the ends to prevent
the filterwicks,whichhad beenwetwith buffer, fromdrying out.
Focusing was performed at 20 μA with maximum values of
4500 V, 50 μA, and 200 mW. Focusingwas performed for a target
of 20 kVh. The focused peptides were acidified using 20 μl of
acidic mixture (0.5% acetic acid, 1% TFA and 2% acetonitrile).
They were then subjected to desalting and LC–MS/MS analysis.
Each sample was analyzed three times by LC–MS/MS.Protein digestion was analyzed using online high perfor-
mance liquid chromatography–tandem mass spectrometry
(LC–MS/MS). The LC–MS/MS setup was similar to that de-
scribed in a previous study [11]. Briefly, after the samples were
processed in the OFFGEL fractionator, the 12 fractions were
clarified to prevent clogging the trapping column with low
protein/peptide binding spin filters (0.65 μm pore size) from
Millipore. The 12 peptide fractions were infused separately
online to a Thermo Electron Finnigan linear ion trap mass
spectrometer (LTQ) operated in positive ion mode via a HPLC
Agilent 1200 LC system, equipped with a self-packed column
(150 μm × 120 mm) at a flow rate of 2 μl/min. The pre-column
was washed with mobile phase (95% ACN, 0.1% formic acid)
for 20 min to remove any contaminants from the OFFGEL
fractionation and the flow was diverted to the separation
column (Agilent Zorbax 300SB-C18, 3.5 μm, 75 μm × 150 mm)
at a flow rate of 250 nl/min. The peptides were separated and
eluted with a linear gradient of 10–60% solution B (0.1% formic
acid) in 84 min. Reverse phase-high performance liquid
chromatography (RP-HPLC) separation was performed on a
Suveyer HPLC system (Thermo Fisher Scientific) equipped
with a self-packed column (75 μm × 120 mm) at a flow rate of
250 nl/min. An LTQ-Orbitrap instrument (Thermo Fisher
Scientific) was operated in data-dependent mode. The mass
spectrometer was set that each full MS scan was followed by
10 most intense ions for MS/MS with charge ≥+2 and the
following Dynamic Exclusion™ settings were used: repeat
counts, 1; repeat duration, 120 s; exclusion duration, 180 s.
The full mass was scanned in Orbitrap analyzer with R =
60,000 (defined at m/z 400), and the subsequent MS/MS
analyses were performed in LTQ analyzer.
2.4. Database searching for label-free quantification
All MS/MS spectra were searched using Maxquant software
(1.3.0.5) against the human International Protein Index (IPI)
database (version 3.87) [12]. Each genuine protein sequence was
followed by the reversed amino acid sequence. Two missing
cleavage sites were allowed. The tolerances of peptides and
fragment ions were set at 6 ppm and 0.5 Da, respectively. The
peptide and protein false discovery rate (FDR) was fixed at no
more than 0.01. Peptide andprotein abundance informationwere
used for label-free quantification as described elsewhere [13].
In our initial studies, we analyzed myocardial proteins of
right ventricle tissue from 10 TOF and 10 non-TOF patients. All
peptides and proteins identified in this study are listed with
posterior error probability values in Table 2.
2.5. Gene ontology analysis
Gene ontology (GO) categories of the identified proteins was
performed using the STRAP developed by the Cardiovascular
Proteomics Center at the Boston University School of Medicine
(http://www.bumc.bu.edu/cardiovascularproteomics/cpctools/
strap/) on the basis of Fisher's exact test (P < 0.01) [14]. Using a
cumulative distribution function-basedmethod, a group of up-
and downregulated genes from each data set was statistically
tested using the genes' association with each GO entry. We
selected the most significant GO terms for each tissue and
eliminated redundant GO terms based on the number of genes
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Enriched GO categories under biological process andmolecular
function were evaluated for differential proteins.
2.6. Immunoblotting
We performed immunoblotting to confirm the results ob-
tained from TOF-MS/MS for four proteins: 6-phosphofructo-2-
kinase/fructose-2,6-biphosphatase 2 (PFKFB2), lysocardiolipin
acyltransferase 1 (LCLAT1), lumican (LUM), and versican
(VCAN). These proteins are representative of glycolysis, metab-
olism, and extracellular-matrix-related proteins involved in
RV remodeling. Blots were processed using commercially avail-
able anti-human antibodies: human PFKFB2 polyclonal anti-
body (AP8146a, Abgent), LCLAT1 polyclonal antibody (AP5723b,
Abgent), lumican polyclonal antibody (AP7605a Abgent),
versican polyclonal antibody (ab19345 Abcam), and β-actin
rabbit monoclonal antibody (4970, Cell Signaling Technology).
The secondary antibody used was Dylight 800 labeled affinity
antibody to rabbit IgG (072-07-15-06 KPL).
In brief, myocardia were solubilized in Laemmli buffer
containing 2-mercaptoethanol. The proteins obtained were
separated on 10% SDS polyacrylamide gels. Equal amount of
protein (50 μg/lane), estimated using bicinchoninic acid re-
agent, was loaded. Proteins were then transferred onto nitro-
cellulose (Immobilon-P Millipore) and the blots were blocked
The membranes were blocked with 5% nonfat milk in Tris-
buffered saline Tween 20 (TBST) for 2 h at room temperature
and then probed with antibodies. Each primary antibody
involved in this studywasusedaccording to themanufacturer's
instructions and diluted to 1:1000–2500. After incubation with
corresponding secondary antibodies, the bands were detected
using a kit (KPL), diluted to 1:5000, and visualized using an
Odyssey infrared imaging system (Odyssey Thera Inc.). Quan-
titative densitometric image analysis was performed (ImageJ
1.46; http://imagej.nih.gov/ij/). The densitometry of the 45 kDa
band was used to normalize the immunoblotting densitome-
tries. Equal loading was confirmed by β-actin immunoblotting.
2.7. Real-time quantitative PCR analysis
The two-step quantitative real-time RT-PCR (QRT-PCR) SYBR
Green method (Applied Biosystems) was used to compare and
confirm the levels of selected interesting genes. Total RNAwas
extracted from frozen tissue samples using a RNAsimple Total
RNA Kit (Tiangen), as described in the manufacturer's proto-
col. First-strand cDNA was synthesized using equal amounts
of RNA with random primers and PrimeScript RT reverse
transcriptase (Takara). The real-time polymerase reaction was
conducted using SYBR Green Power Premix (ABI) according
to the manufacturer's instructions. The reactions were per-
formed in a total volume of 10 μl and 1.0 μl of cDNA sample
was used as a template. An Applied Biosystems 7900 real-time
PCR System (ABI) was used as follows: 1 cycle of 10 s at 95 °C
followed by 40 cycles of 15 s at 95 °C and 60 s at 60 °C,
according to the manufacturer's instructions. The level of
mRNA expression was determined with a standard curve
and normalized to the mRNA level of 18S ribosomal RNA (18S
rRNA). The primer was obtained from Ruijie Bio. (China).
The sequences optimized for real-time PCR were as follows:PFKFB2 (sense, 5′-TACGACTTCTTTCGGCATGA; antisense, 3′-
CTCCTCTCCCGGGTTGTATT), LCLAT1 (sense, 5′-TGTGGAATT
GCCTGATGCGAT; antisense, 3′-TCCAGGAACACCTTTGAGACT),
LUM (sense, 5′-CCACCACACCTGACAGAGT; antisense, 3′-CAAG
TTGATTGACCTCCAGG), VCAN (sense, 5′-GGTATAGCCCATC
TTCCATTTCC and antisense, 3′-TCCTGGTTGGGTCTCCAATTC),
and 18S rRNA (sense 5′-GTAACCCGTTGAACCCCATT; antisense,
3′-CCATCCAATCGGTAGTAGCG). All samples were prepared in
triplicate to determine their threshold cycle (Ct).Where deviation
for each triplicate was higher than 0.3 cycles, Ct was not
considered. We show the quantification (n-fold vs. 18S) of three
rounds of PCR from at least three independent assays. All
samples were run in triplicate with 18S rRNA as an internal
control. The sample, control, and target gene were run on the
same plate. The fluorescence threshold value was calculated
using anABI PrismSequenceDetection System, version 2.4 (ABI).
2.8. Immunohistochemistry
The specimens were fixed overnight in 4% paraformaldehyde,
embedded in paraffin wax, and cut to produce 5 μm-thick
sections. For immunohistochemical staining, sections were
dewaxed in xylene and rehydrated in serial alcohol. Endoge-
nous peroxidase was blocked by immersing the sections in
0.3% H2O2 in methanol for 20 min at room temperature. The
specimens were blocked with 3% nonfat milk for 2 h at room
temperature and then treated using rabbit polyclonal antibod-
ies against PFKFB2, LCLAT1, LUM, and VCAN at 4 °C for 12–14 h.
Anti-PFKFB2 (AP8146a, Abgent), anti-LCLAT1 (AP5723b, Abgent),
anti-LUM (AP7605a, Abgent), and anti-VCAN (ab19345 Abcam)
were used in accordance with manufacturers' instructions at
dilutions of 1:500–1:800. Antigen–antibody complexes were
detected using a DAB peroxidase substrate kit according to the
manufacturer's protocol (Dako). The negative controls were
subjected to the same protocol excepting only that PBS was
used instead of the primary antibody. Immunohistochemical
staining was semi-quantified using Image Pro Plus 6.0 software
on 10 fields of myocardial specimens.
2.9. Statistics
Data were analyzed using the SPSS 17.0 (version 17.0) software
package. For clinical data, continuous variables are expressed
as mean ± standard deviation (SD) and categorical data are
given as numerical values or as percentages. The Student's t
or Wilcoxon rank sum tests for continuous variables, the
chi-square test for categorical variables, as appropriate. For
proteomic analysis, the Student's test was used to compare
average ratios between groups. For gene ontology analysis, we
corrected values for Bonferroni test. P-values below 0.05 were
considered statistically significant.3. Results
3.1. Patients' clinical characteristics
The TOF and non-TOF groups showed no differences in mean
height, mean weight, mean age, left ventricular ejection
fraction (LVEF), and left ventricular shortening fraction (LVSF)
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TOF group (P < 0.001). Peak pulmonary transvalvular gradient
(P < 0.001), flow rates of main pulmonary artery (MPA, P < 0.05),
and RVmyocardial performance index (Tei index, P < 0.05) were
significantly higher in the TOF group. The RV hypertrophy was
confirmed by echocardiography or cardiac CT. Both the NYU
PHFI and modified Ross scores were significantly higher in the
TOF group than in the non-TOF group (P < 0.001). Cyanosis,
tachycardia, tachypnea or dyspnea, hepatomegaly, and failure
to thrive were seen among TOF patients. In brief, TOF patients
showed early, mild clinically signs of RV dysfunction. Clinical
characteristics are shown in Table 1.
3.2. Identification of 136 differentially expressed proteins
by RV myocardium proteomic analysis
In the proteomic analysis a total of 2030 proteins were
identified. Of these, 136 proteinswere differentially expressed,
showing at least 2.0-fold changes (P < 0.05) (Table 2) between
two groups. Of these, 53 proteins were up-regulated and 83
proteins were down-regulated.
3.3. GO analysis of differentially expressed proteins
Upon gene ontology (GO) analyses of proteins found to be
differentially expressed between TOF and non-TOF samples,
reasonable representations of biological process and molecular
function were obtained. GO analysis showed the most sig-
nificantly upregulated processes to be in the categories of
phosphate transport, response to stimulus, inorganic anion
transport, and cell adhesion. Downregulated processes were
dominated by energy pathways. The differentially expressed
proteins covered 348 biological processes corresponding to
cellular process, developmental processes, growth, immune
system processes, interaction with cells and organisms, local-
ization, metabolic processes, regulation, reproduction, and
response to stimulus. They also covered 188 molecular func-
tions corresponding to antioxidant activity, binding, catalytic
activity, enzyme regulator activity, molecular transducer activ-
ity, structural molecule activity, and transcription regulatorTable 1 – Clinical information of the patients with and without
Height (cm)
Weight (kg)
Age (month)
Gender (male/female)
Oxygen saturation (SO2)
Left ventricular ejection fraction (LVEF)
Left ventricular fractional shortening (LVFS)
Peak pulmonary transvalvular gradient (mm Hga)
Flow rates of main pulmonary artery (MPA; m/s)
RV myocardial performance index (Tei index)
Modified Ross score
New York University Pediatric Heart Failure Index (NYU PHFI)
⁎ P < 0.05 TOF vs. non-TOF.
⁎⁎ P < 0.001 TOF vs. non-TOF.
a 1 mm Hg = 0.133 kPa.activity. Of these, 88% could be assigned to a known function. 14
proteins could not be assigned to any functions (Table 3) and
may be novel proteins involved with RV hypertrophy. The
categories and relative occurrence are given in Fig. 1.
3.4. Immunoblotting
Western blot analysis was performed to confirm that differ-
entially expressed proteins had been detected by proteomics
profiling. We validated the proteomic results using 4 proteins,
PFKFB2, LCLAT1, LUM, and VCAN (Fig. 2). These proteins were
here considered representative of pathways involved in RV
remodeling. β-Actin was used as a loading control. Western
blot analysis showed the protein expression of PFKFB2 (TOF/
non-TOF ratio 2.43, P < 0.05) to be higher in the TOF group and
the protein expression of LCLAT1 (TOF/non-TOF ratio 0.32,
P < 0.05), LUM (TOF/non-TOF ratio 0.47, P < 0.05), and VCAN
(TOF/non-TOF ratio 0.41, P < 0.05) to be lower in the non-TOF
group.
3.5. Real time-PCR
Changes in the levels of mRNA expression of PFKFB2, LCLAT1,
LUM, and VCAN were detected using real-time PCR (Fig. 3).
mRNA expression was normalized to the control, 18S rRNA.
RT-PCR analysis showed PFKFB2 mRNA expression (TOF/
non-TOF ratio 2.23, P < 0.05) to be higher in the TOF group
than in the non-TOF group and the level of mRNA expression
of LCLAT1 (TOF/non-TOF ratio 0.39, P < 0.05) and LUM (TOF/
non-TOF ratio 0.41, P < 0.05) to be lower in the TOF group. The
mRNA expression of VCAN (TOF/non-TOF ratio 1.32, P > 0.05)
showed no significant change between the two groups.
3.6. Immunohistochemical analysis
In comparison between non-TOF and TOF by immunohisto-
chemical analysis, protein PFKFB2 (TOF/non-TOF ratio 1.52,
P < 0.05) was more strongly stained in TOF myocardia than
non-TOF myocardia (Fig. 4A, B, C, D, and E), but LCLAT1
protein (TOF/non-TOF ratio 0.63, P < 0.05) was more stronglyTOF.
Non-TOF TOF P
78.70 ± 14.967 69.10 ± 4.533 0.377
9.36 ± 3.66 8.25 ± 1.30 0.068
10.90 ± 4.701 9.30 ± 3.164 0.384
4/6 9/1 0.057
98.80 ± 4.442 84.50 ± 6.786 0.001 ⁎⁎
68.540 ± 5.215 61.170 ± 6.029 0.311
37.56 ± 4.00 38.450 ± 4.65 0.652
25.86 ± 9.67 78.62 ± 16.32 0.000 ⁎⁎
2.26 ± 0.15 4.04 ± 1.37 0.001 ⁎
0.23 ± 0.02 0.42 ± 0.05 0.012 ⁎
2.4 ± 0.84 5.70 ± 0.95 0.000 ⁎⁎
5.2 ± 1.69 9.00 ± 2.00 0.000 ⁎⁎
Table 2 – Differentially expressed proteins (variations >2.0 fold, P < 0.05) in TOF and non-TOF right ventricle tissue
specimens.
No. IPI accession
number a
Gene
symbol
Protein Seq. cov
(%) c
TOF spectrum
count b
Non-TOF
spectrum
count b
Fold
change
P-value
1 IPI00022895 A1BG Alpha-1B-glycoprotein 46.78 33.06 ± 15.75 13.12 ± 5.12 2.52 0.0158
2 IPI00479760 AAK1 AP2-associated protein kinase 1 29.82 69.98 ± 35.76 32.68 ± 3.336 2.14 0.0034
3 IPI00009532 ABAT 4-Aminobutyrate aminotransferase,
mitochondrial
39.17 27.93 ± 2.19 164.46 ± 11.98 0.17 0.0256
4 IPI00479296 ABCA8 ATP-binding cassette sub-family A
member 8
66.07 15.51 ± 4.92 52.75 ± 3.88 0.29 0.0352
5 IPI00894097 AEBP1 Adipocyte enhancer-binding protein 1 12.30 4.68 ± 1.07 24.64 ± 2.19 0.19 0.0436
6 IPI00016568 AK4 Adenylate kinase isoenzyme 4,
mitochondrial
19.78 71.39 ± 14.38 145.84 ± 7.47 0.49 0.0029
7 IPI00940222 AKAP12 A-kinase anchor protein 12 54.93 34.13 ± 3.16 74.47 ± 3.64 0.46 0.0066
8 IPI00965719 ANK2 Ankyrin-2 64.85 12.41 ± 2.46 49.65 ± 5.31 0.25 0.0016
9 IPI00514053 ARCN1 Coatomer subunit delta 20.75 3.10 ± 1.04 31.03 ± 3.87 0.1 0.0401
10 IPI00418431 ASPN Asporin 48.81 124.12 ± 10.97 319.61 ± 11.71 0.39 0.0107
11 IPI00010790 BGN Biglycan 69.04 102.40 ± 4.39 335.12 ± 18.92 0.3 0.0453
12 IPI00021727 C4BPA C4b-binding protein alpha chain 25.39 38.55 ± 4.64 16.26 ± 2.194 2.37 0.0001
13 IPI00022395 C9 Complement component C9 23.86 145.75 ± 32.21 31.82 ± 5.93 4.58 0.0257
14 IPI00843811 C9orf123 Transmembrane protein C9orf123 18.94 46.54 ± 17.32 6.21 ± 1.96 7.5 0.0070
15 IPI00027466 CA4 Carbonic anhydrase 4 26.06 6.21 ± 2.17 43.44 ± 3.93 0.14 0.0150
16 IPI00465436 CAT Catalase 74.63 192.38 ± 15.36 58.96 ± 7.08 3.26 0.0104
17 IPI00027626 CCT6A T-complex protein 1 subunit zeta 63.95 80.68 ± 32.18 167.56 ± 8.55 0.48 0.0176
18 IPI00010180 CES1 Liver carboxylesterase 1 23.00 12.41 ± 3.54 52.75 ± 5.28 0.24 0.0324
19 IPI00009028 CLEC3B Tetranectin 64.24 3.10 ± 1.21 37.24 ± 3.52 0.08 0.0162
20 IPI00024776 CLGN Calmegin 29.54 31.03 ± 12.86 65.16 ± 3.09 0.48 0.0287
21 IPI00400826 CLU Clusterin 39.63 12.41 ± 4.32 71.37 ± 5.86 0.17 0.0045
22 IPI00176193 COL14A1 Collagen alpha-1(XIV) chain 62.16 217.21 ± 34.21 471.65 ± 18.55 0.46 0.0131
23 IPI00856012 COL6A6 Collagen alpha-6(VI) chain 54.33 83.78 ± 32.12 226.52 ± 12.16 0.37 0.0085
24 IPI00163230 COPS6 COP9 signalosome complex subunit 6 33.51 15.51 ± 32.34 71.37 ± 3.88 0.22 0.0049
25 IPI00645720 COQ7 Ubiquinone biosynthesis protein
COQ7 homolog
23.23 34.13 ± 12.09 102.40 ± 8.78 0.33 0.0023
26 IPI00017601 CP Ceruloplasmin 35.86 117.91 ± 38.79 245.14 ± 15.51 0.48 0.0072
27 IPI00917030 CPVL Probable serine carboxypeptidase CPVL 12.36 3.10 ± 0.83 43.44 ± 5.70 0.07 0.0490
28 IPI00031801 CSDA DNA-binding protein A 28.16 31.03 ± 14.28 3.10 ± 0.98 10.01 0.0036
29 IPI00002824 CSRP2 Cysteine and glycine-rich protein 2 62.92 39.07 ± 8.67 11.25 ± 2.29 3.47 0.0004
30 IPI00012835 CTBP1 C-terminal-binding protein 1 12.98 18.62 ± 5.43 89.99 ± 6.45 0.21 0.0082
31 IPI00010120 CTBP2 C-terminal-binding protein 2 50.33 6.21 ± 2.14 24.82 ± 2.45 0.25 0.0023
32 IPI00019411 CYP2J2 Cytochrome P450 2 J2 50.64 34.13 ± 23.56 3.10 ± 0.96 11 0.0441
33 IPI00028387 DDRGK1 DDRGK domain-containing protein 1 18.73 3.10 ± 1.24 34.13 ± 3.09 0.09 0.0085
34 IPI00024462 DHODH Dihydroorotate dehydrogenase
(quinone), mitochondrial
36.44 46.36 ± 2.45 18.67 ± 5.32 2.48 0.0203
35 IPI00454647 DHRS4-AS1 Putative uncharacterized protein
DHRS4-AS1
14.33 18.14 ± 7.63 7.85 ± 2.27 2.31 0.0005
36 IPI00396435 DHX15 Putative pre-mRNA-splicing factor
ATP-dependent RNA helicase DHX15
68.99 18.62 ± 9.21 55.85 ± 4.58 0.33 0.0015
37 IPI00465105 DNAJA4 DnaJ homolog subfamily A member 4 34.78 34.13 ± 12.34 3.10 ± 0.92 11.00 0.0109
38 IPI00556073 DNAJB6 DnaJ homolog subfamily B member 6 15.84 71.37 ± 22.98 21.72 ± 2.94 3.28 0.0162
39 IPI00220813 EFEMP1 EGF-containing fibulin-like extracellular
matrix protein 1
68.99 9.31 ± 3.01 43.44 ± 3.64 0.21 0.0480
40 IPI00003519 EFTUD2 116 kDa U5 small nuclear
ribonucleoprotein component
48.92 18.62 ± 2.90 49.65 ± 2.98 0.38 0.0009
41 IPI00102069 EIF3M Eukaryotic translation initiation factor
3 subunit M
59.52 37.24 ± 14.32 3.10 ± 1.02 12.00 0.0385
42 IPI00411704 EIF5A Eukaryotic translation initiation
factor 5A-1
52.33 21.72 ± 6.82 93.09 ± 6.03 0.23 0.0079
43 IPI00012510 EMILIN2 EMILIN-2 49.24 102.40 ± 41.05 49.65 ± 3.64 2.06 0.0352
44 IPI00303161 ESAM Endothelial cell-selective adhesion
molecule
13.31 46.54 ± 32.12 6.21 ± 1.96 7.50 0.0183
45 IPI00297550 F13A1 Coagulation factor XIII A chain 25.44 21.72 ± 12.23 58.96 ± 2.71 0.37 0.0316
46 IPI00019568 F2 Prothrombin 46.86 37.24 ± 7.18 105.50 ± 6.735 0.35 0.0345
47 IPI00294615 FBLN5 Fibulin-5 61.22 52.75 ± 20.94 136.53 ± 5.70 0.39 0.0038
48 IPI00298497 FGB Fibrinogen beta chain 28.04 77.57 ± 25.10 207.90 ± 16.90 0.37 0.0186
49 IPI00021891 FGG Fibrinogen gamma chain 30.30 127.22 ± 40.18 269.96 ± 12.42 0.47 0.0083
(continued on next page)
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Table 2 (continued)
No. IPI accession
number a
Gene
symbol
Protein Seq. cov
(%) c
TOF spectrum
count b
Non-TOF
spectrum
count b
Fold
change
P-value
50 IPI00293425 FXN Frataxin, mitochondrial 66.55 12.41 ± 3.85 49.65 ± 3.65 0.25 0.0053
51 IPI00968027 GC Vitamin D-binding protein 74.40 37.24 ± 18.3 86.88 ± 15.43 0.43 0.0327
52 IPI00333763 GLRX5 Glutaredoxin-related protein 5,
mitochondrial
68.63 24.82 ± 15.43 55.85 ± 3.81 0.44 0.0032
53 IPI00215687 GLS Glutaminase kidney isoform,
mitochondrial
35.01 52.75 ± 13.45 21.72 ± 2.55 2.43 0.0225
54 IPI00894287 HDLBP High density lipoprotein binding protein 50.33 61.66 ± 13.54 13.85 ± 3.46 4.45 0.0004
55 IPI00003566 HOMER1 Homer protein homolog 1 34.71 3.10 ± 0.24 31.03 ± 3.27 0.1 0.0001
56 IPI00477597 HPR Haptoglobin-related protein 33.77 6.21 ± 2.40 49.65 ± 5.70 0.13 0.0431
57 IPI00022488 HPX Hemopexin 23.40 167.56 ± 15.27 341.33 ± 14.62 0.49 0.0057
58 IPI00555565 HSP90AB4P heat shock protein HSP 90-beta 4 27.21 101.54 ± 36.42 32.75 ± 27.54 3.10 0.0100
59 IPI00217474 IFI16 Gamma-interferon-inducible protein 16 14.87 37.24 ± 9.40 9.31 ± 4.06 4.00 0.0152
60 IPI00018300 IFIT1 Interferon-induced protein with
tetratricopeptide repeats 1
44.35 22.99 ± 4.98 8.32 ± 3.68 2.76 0.0100
61 IPI00423461 IGHA2 Ig alpha-2 chain C region 36.08 41.65 ± 15.43 14.29 ± 2.19 2.91 0.0078
62 IPI00896380 IGHM Ig mu chain C region 49.94 3.10 ± 0.68 62.06 ± 6.72 0.05 0.0124
63 IPI00005198 ILF2 Interleukin enhancer-binding factor 2 52.32 43.44 ± 11.48 117.91 ± 6.51 0.37 0.0385
64 IPI00032328 KNG1 Kininogen-1 21.13 9.31 ± 2.17 52.75 ± 24.63 0.18 0.048
65 IPI00299033 KPNA3 Importin subunit alpha-3 71.77 18.62 ± 3.50 46.54 ± 2.19 0.4 0.0027
66 IPI00012578 KPNA4 Importin subunit alpha-4 72.57 12.41 ± 4.38 43.44 ± 13.93 0.29 0.0287
67 IPI00386803 LASP1 LIM and SH3 domain protein 1 50.55 18.62 ± 4.54 49.65 ± 12.00 0.38 0.0164
68 IPI00419643 LCLAT1 Lysocardiolipin acyltransferase 1 36.82 11.92 ± 2.36 42.05 ± 2.17 0.28 0.0100
69 IPI00009950 LMAN2 Vesicular integral-membrane protein
VIP36
35.24 3.10 ± 0.73 24.82 ± 2.85 0.13 0.0361
70 IPI00027847 LPL Lipoprotein lipase 25.08 6.21 ± 3.67 24.82 ± 12.45 0.25 0.0499
71 IPI00386687 LRRFIP1 Leucine-rich repeat flightless-
interacting protein 1
29.71 31.03 ± 2.65 6.21 ± 1.31 5.00 0.0392
72 IPI00020986 LUM Lumican 27.78 39.09 ± 12.87 81.29 ± 30.11 0.48 0.0038
73 IPI00107722 MCEE Methylmalonyl-CoA epimerase,
mitochondrial
23.11 56.42 ± 16.54 16.34 ± 2.16 3.45 0.0021
74 IPI00022300 METTL7A Methyltransferase-like protein 7A 73.86 12.41 ± 2.28 52.75 ± 4.64 0.24 0.0116
75 IPI00654820 MT-ATP6 ATP synthase subunit a 73.25 3.10 ± 0.35 27.93 ± 2.29 0.11 0.0085
76 IPI00102685 MYADM Myeloid-associated differentiation marker 50.27 40.33 ± 7.15 9.31 ± 2.09 4.33 0.0332
77 IPI00790503 MYH10 Myosin-10 58.80 108.60 ± 24.65 217.21 ± 31.92 0.5 0.0407
78 IPI00760846 MYO18A Myosin-XVIIIa 33.78 52.75 ± 32.65 114.81 ± 7.32 0.46 0.0261
79 IPI00797126 NACA Nascent polypeptide-associated complex
subunit alpha
17.89 148.94 ± 54.71 74.47 ± 5.12 2.00 0.0401
80 IPI00926519 NAGK N-acetyl-D-glucosamine kinase 41.66 6.21 ± 2.36 24.82 ± 2.19 0.25 0.0401
81 IPI00293817 NAPG Gamma-soluble NSF attachment protein 44.56 13.67 ± 8.16 3.56 ± 3.09 3.84 0.0145
82 IPI00855737 NEXN Nexilin 17.66 9.31 ± 3.17 34.13 ± 6.23 0.27 0.0314
83 IPI00465264 NLRX1 NLR family member X1 45.79 40.3413.82 93.09 ± 6.21 0.43 0.0352
84 IPI00299000 PA2G4 Proliferation-associated protein 2G4 75.50 43.44 ± 20.62 9.31 ± 1.50 4.67 0.0229
85 IPI00221111 PACSIN2 Protein kinase C and casein kinase
substrate in neurons protein 2
37.28 6.21 ± 1.60 49.65 ± 23.93 0.13 0.0227
86 IPI00980056 PACSIN3 Protein kinase C and casein kinase
substrate in neurons protein 3
33.48 15.51 ± 4.29 68.27 ± 15.62 0.23 0.0480
87 IPI00298547 PARK7 Protein DJ-1 63.55 77.57 ± 18.24 24.82 ± 4.09 3.125 0.0120
88 IPI00167134 PDLIM3 PDZ and LIM domain protein 3 60.28 12.41 ± 3.16 89.99 ± 17.52 0.14 0.0134
89 IPI00220808 PFKFB2 6-Phosphofructo-2-kinase/
fructose-2,6-bisphosphatase 2
32.04 34.13 ± 7.82 6.21 ± 1.31 5.5 0.0351
90 IPI00299977 PHPT1 14 kDa phosphohistidine phosphatase 52.58 15.51 ± 5.92 43.44 ± 2.62 0.36 0.0273
91 IPI00216694 PLS3 Plastin-3 46.59 58.96 ± 18.65 145.84 ± 11.71 0.4 0.0055
92 IPI00744711 PNPT1 Polyribonucleotide
nucleotidyltransferase 1, mitochondrial
30.99 43.44 ± 32.59 102.40 ± 6.04 0.42 0.0227
93 IPI00165506 POLDIP2 Polymerase delta-interacting protein 2 19.09 108.81 ± 45.36 28.17 ± 2.45 3.86 0.0354
94 IPI00470502 PPA2 Inorganic pyrophosphatase 2,
mitochondrial
32.01 74.47 ± 23.43 152.05 ± 6.93 0.49 0.0088
95 IPI00439948 PPP1R13L RelA-associated inhibitor 41.25 40.33 ± 12.75 9.31 ± 1.53 4.33 0.048
96 IPI00295252 PREX1 Phosphatidylinositol
3,4,5-trisphosphate-dependent Rac
exchanger 1 protein
54.17 31.03 ± 14.58 6.21 ± 1.31 5.00 0.0388
97 IPI00305068 PRPF6 Pre-mRNA-processing
factor 6
28.27 48.86 ± 17.47 17.94 ± 2.19 2.72 0.0092
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Table 2 (continued)
No. IPI accession
number a
Gene
symbol
Protein Seq. cov
(%) c
TOF spectrum
count b
Non-TOF
spectrum
count b
Fold
change
P-value
98 IPI00024821 PSMD14 26S proteasome non-ATPase regulatory
subunit 14
53.03 27.92 ± 8.22 65.16 ± 4.25 0.43 0.0186
99 IPI00856076 PUF60 Poly(U)-binding-splicing factor PUF60 24.81 40.33 ± 9.78 12.41 ± 3.00 3.25 0.024
100 IPI00016339 RAB5C Ras-related protein Rab-5C 54.09 40.33 ± 13.64 80.68 ± 4.19 0.5 0.0054
101 IPI00024320 RBM3 Putative RNA-binding protein 3 61.81 28.50 ± 2.78 12.48 ± 4.57 2.28 0.0108
102 IPI00219335 RPL3L 60S ribosomal protein L3-like 61.89 40.34 ± 17.49 12.41 ± 2.17 3.25 0.0073
103 IPI00003918 RPL4 60S ribosomal protein L4 51.06 80.68 ± 29.90 15.51 ± 2.64 5.2 0.0046
104 IPI00221088 RPS9 40S ribosomal protein S9 31.78 89.55 ± 33.43 16.83 ± 2.62 5.32 0.0036
105 IPI00012512 RRAS2 Ras-related protein R-Ras2 56.66 24.82 ± 4.69 3.10 ± 0.97 8.00 0.0072
106 IPI00220558 RYR1 Ryanodine receptor 1 67.02 18.62 ± 4.50 55.85 ± 5.02 0.33 0.0206
107 IPI00329784 RYR3 Ryanodine receptor 3 52.02 46.54 ± 16.07 18.62 ± 2.61 2.50 0.0403
108 IPI00022275 SACM1L Phosphatidylinositide phosphatase SAC1 74.87 9.31 ± 1.72 37.24 ± 2.85 0.25 0.0197
109 IPI00062266 SCRN2 Secernin-2 74.50 43.44 ± 32.12 9.31 ± 1.50 4.67 0.0375
110 IPI00847635 SERPINA3 Alpha-1-antichymotrypsin 22.67 9.31 ± 1.01 62.06 ± 5.27 0.15 0.0006
111 IPI00027482 SERPINA6 Corticosteroid-binding globulin 13.48 6.21 ± 12.32 24.82 ± 2.45 0.25 0.0041
112 IPI00293074 SLC44A2 Choline transporter-like protein 2 22.29 15.51 ± 4.34 52.75 ± 2.94 0.29 0.0269
113 IPI00893850 SMTN Smoothelin 71.10 31.03 ± 3.83 9.31 ± 1.48 3.33 0.0215
114 IPI00299095 SNX2 Sorting nexin-2 73.03 9.31 ± 6.94 34.13 ± 2.75 0.27 0.0453
115 IPI00291419 SOAT2 Sterol O-acyltransferase 2 25.50 3.10 ± 0.35 27.93 ± 3.05 0.11 0.0261
116 IPI00027827 SOD3 Extracellular superoxide dismutase
[Cu–Zn]
35.07 55.85 ± 13.88 111.71 ± 35.51 0.5 0.0287
117 IPI00103415 STAT5B Signal transducer and activator of
transcription 5B
47.16 3.10 ± 31.85 27.93 ± 3.06 0.11 0.0352
118 IPI00019903 TACO1 Translational activator of cytochrome
c oxidase 1
29.40 37.24 ± 11.85 96.19 ± 5.52 0.39 0.0344
119 IPI00386607 TBCD Tubulin-specific chaperone D 41.48 83.05 ± 34.85 35.12 ± 3.09 2.36 0.0130
120 IPI00160479 TECRL Trans-2,3-enoyl-CoA reductase-like 56.55 6.21 ± 2.84 37.24 ± 8.07 0.17 0.0458
121 IPI00385317 TENC1 Tensin-like C1 domain-containing
phosphatase
44.02 28.80 ± 10.35 10.96 ± 2.64 2.63 0.0209
122 IPI00022462 TFRC Transferrin receptor protein 1 57.83 161.36 ± 57.98 68.27 ± 4.09 2.36 0.0261
123 IPI00794391 THSD4 Thrombospondin type-1
domain-containing protein 4
45.66 6.21 ± 2.32 37.24 ± 3.81 0.17 0.0147
124 IPI00001541 TIMM9 Mitochondrial import inner
membrane translocase subunit Tim9
12.09 3.10 ± 0.53 21.72 ± 2.56 0.14 0.0199
125 IPI00063130 TMEM205 Transmembrane protein 205 37.26 21.72 ± 9.38 46.54 ± 2.19 0.47 0.0499
126 IPI00005087 TMOD3 Tropomodulin-3 43.50 149.04 ± 48.23 73.02 ± 2.29 2.04 0.0383
127 IPI00100247 TMX4 Thioredoxin-related transmembrane
protein 4
37.78 159.74 ± 33.85 37.90 ± 3.57 4.21 0.0052
128 IPI00939667 TPP1 Tripeptidyl-peptidase 1 34.68 74.47 ± 3.56 148.94 ± 35.63 0.50 0.0344
129 IPI00301561 TRIP6 Thyroid receptor-interacting protein 6 44.04 27.93 ± 3.43 3.10 ± 0.89 9.00 0.0199
130 IPI00292858 TYMP Thymidine phosphorylase 40 21.11 ± 11.26 7.29 ± 4.57 2.89 0.0397
131 IPI00830039 U2AF2 Splicing factor U2AF 65 kDa subunit 18 15.51 ± 9.34 40.34 ± 2.65 0.38 0.0480
132 IPI00003965 USP7 Ubiquitin carboxyl-terminal hydrolase 7 30 27.96 ± 16.28 9.16 ± 2.19 3.05 0.0200
133 IPI00215631 VCAN Versican core protein 72 71.37 ± 36.73 170.66 ± 8.56 0.42 0.0034
134 IPI00032050 WBP2 WW domain-binding protein 2 14 34.13 ± 8.73 3.10 ± 0.99 10.00 0.0131
135 IPI00922067 XPNPEP3 Probable Xaa-Pro aminopeptidase 3 15 3.10 ± 1.58 31.03 ± 2.94 0.10 0.0230
136 IPI00166738 ZADH2 Zinc-binding alcohol dehydrogenase
domain-containing protein 2
30 34.13 ± 5.07 3.10 ± 0.87 11.00 0.0333
a Accession number from EMBL-EBI (International Protein Index, IPI).
b Scores based on the average of each sample's spectral counting.
c Percentage of sequence coverage.
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G, H, I, and J). LUM protein (TOF/non-TOF ratio 0.59, P < 0.05)
was more strongly stained in TOF extracellular regions than in
non-TOF extracellular regions (Fig. 4K, L, M, N, and O). Levels of
VCAN protein (TOF/non-TOF ratio 0.68, P < 0.05) were clearly
higher in TOF extracellular regions (Fig. 4P, Q, R, S, and T) than
in non-TOF extracellular regions. Semi-quantification graphs
are shown (Fig. 4E, J, O, and T; *, P < 0.05).4. Discussion
Our study profiled differential protein expression during RV
remodeling in developing hearts with congenital malforma-
tion. We speculated that maladaptive response to long-term
pressure overload and chronic hypoxia could be the immedi-
ate causes of the RV remodeling. Some of the differentially
Table 3 – 14 proteins not assigned to any functions. a
Gene
symbol
Location Tissue specificity Biology process Cellular component Molecular function
A1BG 19q13.4 Plasma \ Extracellular region \
C9orf123 9p24.1 \ \ Integral to membraned \
DDRGK1 20p13 Ubiquitously expressed
(at protein level)
\ Endoplasmic reticulum \
DHRS4-AS1 14q11.2 \ \ \ \
DNAJA4 15q25.1 \ Protein folding/response
to heat d
Membraned ATP bindingd/metal ion
bindingd
HPR 16q22.1 \ Metabolic process d Spherical high-density
lipoprotein particle
Catalytic activity d
MYADM 19q13.42 Widely expressed.
Not detected in thymus
\ Integral to membrane \
POLDIP2 17q11.2 \ \ Mitochondrial nucleoid/
nucleus d
DNA bindingd
PPA2 4q25 Detected in brain, gastric
carcinoma, lung, ovary,
skeletal muscle, umbilical
cord blood and a cell
line derived from kidney
proximal tubule
epithelium
Diphosphate metabolic
process b/phosphate-
containing compound
metabolic process d/tRNA
aminoacylation for
protein translationb
Mitochondrial matrix b Inorganic diphosphatase
activity b /magnesium ion
bindingd
SCRN2 17q21.32 \ Proteolysis d Dipeptidase activity d \
TECRL 4q13.1 \ Lipid metabolic process d Cytoplasm/integral to
membraned
Oxidoreductase activity,
acting on the CH–CH
group of donors d
TMX4 20p12 \ Cell redox homeostasis d/
electron transport chaind
Integral to membrane \
WBP2 17q25 Ubiquitous \ \ \
ZADH2 18q22.3 \ Mitochondrion d/
peroxisomec
Nucleotide bindingd/
oxidoreductase activity d/
zinc ion bindingd
\
a Information from UniProt.
b Traceable author statement.
c Inferred from sequence or structural similarity.
d Inferred from electronic annotation.
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certain biological processes related to cardiac remodeling,
including the regulation of glycolysis, oxidation and reduction,
oxidative stress, metabolism, cell death, ion homeostasis,
and protein transport. They showed that RV was affected by
pressure overload and chronic hypoxia in infants with TOF. We
further confirmed the expression of metabolic enzymes, such
as 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2
(PFKFB2) and lysocardiolipin acyltransferase 1 (LCLAT1).
PFKFB2 is mainly expressed in the heart, brain, and lungs.
It belongs to the 6-phosphofructo-2-kinase/fructose-2,6-
bisphosphatase (PFKFB) family [15]. PFKFB2 is the most potent
allosteric activator of phosphofructokinase (PFK-1), which is a
key regulator of glycolytic flux. Cellular levels of PFKFB2
are correlated to the intensity of glycolytic flux. In this way,
the cardiac PFKFB2 isoform is essential to the regulation of
glycolysis in the heart [16]. Minchenko showed that hypoxia
was associated with a slight downregulation of PFKFB2 mRNA
expression in the hearts of affected mice [17]. Unlike
Minchenko, we discovered that protein and mRNA levels of
PFKFB2 were significantly higher in TOF patients than in
unaffected individuals. We speculated that methodological
differences may account for this discrepancy. Specifically, the
mice used in the Minchenko's study were kept in hypoxicenvironments for only 6 h, but in our study, pathophysiolog-
ical hypoxia and malhemodynamics of TOF lasted for at least
8 months. PFKFB2 was also found to be highly expressed in
tissues undergoing tumorigenesis, which preferentially use
glycolysis to meet the tumors' increased energetic and bio-
synthetic requirements (Warburg effect) [18]. Like tumors,
under pathological stress conditions, cardiomyocytes gradu-
ally come to rely on glycolysis to meet their main energy
requirements. This is called cardiac metabolic inflexibility
[19,20]. We also identified other proteins related to glycolysis,
such as PFK-1 and HK (hexokinase), and found that they have
an upward trend in TOF. However, the levels of these proteins
did not show significant differences (data not shown).
Lysocardiolipin acyltransferase 1 (LCLAT1) was recently
shown to catalyze pathological remodeling of CL in response
to oxidative stress in individuals with diabetes, obesity, and
cardiomyopathy, leading to ROS production, mitochondrial
dysfunction, and insulin resistance [21–23]. CL pathological
remodeling by ALCAT1 overexpression leads to the synthesis
of CL with aberrant acyl composition. It has been implicated in
the etiology of mitochondrial dysfunction, including depletion
of linoleic acid and enrichment of DHA content in CL. Ablation
of ALCAT1 has been shown to mitigate oxidative stress and
prevent mitochondrial dysfunction by up-regulating levels of
Fig. 1 – The identified proteins were classified based on known biological process (A) and molecular function (B).
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MFN2 [24,25]. Cao found ALCAT1 expression in liver and heart
to be significantly downregulated in mice with hypothyroid-
ism and upregulated in mice treated with thyroid hormone,
suggesting that changes in LCLAT1 expression can meet
the need for cardiolipin remodeling in response to changes in
mitochondrial activity and ROS levels [23]. Conversely, we
found that the level of expression of protein and mRNA
LCLAT1 decreased in the TOF group. We also found SOD3
level decreased in TOF group. Eva Nozik-Grayck, found that
chronic hypoxic decreased SOD activity and protein expres-
sion, suggesting that hypoxic adaptation did not impairedFig. 2 – Western blot analysis of the levels of proteins in myocar
LUM (C) and VCAN (D) in non-TOF (left panel) and TOF (right pan
representative graph is shown along with the numeric data obta
served as loading control. The bars indicate mean ± SD. Student
(*, P < 0.05, n = 3).mitochondria and ROS level was low [26]. Moreover, cumula-
tive evidence suggests that LCLAT1 didn't relate to pressure
overload increase [27–29]. Our data suggested that LCLAT1
expression may become significantly downregulated during
chronic hypoxia, which decreases levels of oxidative stress
and ROS production.
In normal hearts, fatty acid is the main energy resource.
Loss of metabolic flexibility such as, substantial metabolic
switch from fatty acid oxidation to glycolysis, would be
potentially harmful to heart function [30]. In this extended
study, we observed somewhat similar qualitative changes and
elevations in the levels of proteins related to glycolysis. Nodial tissues. Western blots to detect PFKFB2 (A), LCLAT1 (B),
el). Equal amounts of total protein were loaded (50 μg). A
ined by densitometry analysis (below each panel). β-Actin
's test was performed to evaluate statistical significance.
Fig. 3 – The mRNA expression level of PFKFB2 (A), LCLAT1 (B), LUM (C) and VCAN (D) was further verified by real time-PCR. The
distribution of PFKFB2 was increased (P < 0.05), LCLAT1 and LUM decreased respectively (P < 0.05). VCAN does not show
significant changes between two groups (P > 0.05). The bars indicate mean ± SD. Student's test was performed to evaluate
statistical significance. (*, P < 0.05).
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fatty acid oxidation in our experiment. However, we noted a
substantial decline in lipid metabolic processes relative to
fatty acid oxidation in TOF. For example, CYP2J2 (fatty acid
biosynthetic process), clusterin, high-density lipoprotein bind-
ing protein (lipid transport), lipoprotein lipase (triglyceride
catabolic process), soat2 (lipidmodification), and LCLAT1 (lipid
biosynthetic process) [31–35]. It can be concluded that the
overall rate of general lipid metabolic processes decreases in
response to pathophysiological changes in TOF. This metabol-
ic change decreases cardiac efficiency and energetic utiliza-
tion. Specifically, metabolic inflexibility may be detrimental
to heart function during early phases due to maladaptive
responses.
The extracellular matrix (ECM) protein lumican (LUM)
belongs to a family of small leucine-rich proteoglycans
(SLRPs). Previous studies have shown that LUM contributes
mainly to collagen fiber assembly and organization in fibrotic
lesions in ischemic and reperfused hearts [36]. LUM may be
related to heart failure irrespective of age and sex [37]. Waehre
observed an elevation in total levels of LUM protein in the
pressure-overloaded RV tissue of the mice 7 days after pul-
monary artery banding (PAB) [38]. We found LUM protein and
mRNA to be more abundant in non-TOF samples than in TOF
samples. This was consistent with Hwang's earlier findings
showing decreased LUM mRNA expression in end-stage heart
failure with hypertrophic cardiomyopathy (HCM). Sharing
pathophysiological similarity with TOF, HCM patients showed
dyspnea, heart ventricle hypertrophy, and RVOTO [39]. Some
recent studies have shown that LUM can stop endothelial cells
from activating p38 MAPK and prevent invasion, angiogenic
sprouting, and vessel formation [40]. Many studies have
confirmed that angiogenesis can provide potential compen-
sative benefits for heart failure. Hypertrophy overload can also
cause angiogenic and metabolic genes to meet the greater
demand for nutrients. In this way, angiogenic factors can act
as novel therapeutic targets [41]. These data suggest that the
pattern of LUM expression is different under hypertrophic and
hypoxic conditions but closely associated with the pathology
of tissue repair. Low levels of LUM expression could contribute
to anti-myocardial fibrosis and angiogenesis in TOF pathology.
Versican (VCAN) is a large chondroitin sulfate proteogly-
can, specialized in mediating cell proliferation, adhesion, and
migration. A wide distribution of VCAN was found in variousorgans, including the heart. Its contribution to the pathological
conditions of the vessels such as atherosclerosis and vascular
injury has also been established [42]. Hellman observed the
up-regulation of VCAN at day 1, and this elevated level of
VCAN later subsided to control levels, as recorded on days 6
and 42 [43]. Kern found that G1-containing VCAN and intact
VCAN reducedmyocardial cell–cell association and that VCAN
proteolysis mediates loss of the distal myocardium during
outflow tract development [44]. These results suggested that a
high level of VCAN protein may exhibit an opposing effect on
myocardial cells during cardiac remodeling. Like LUM, we
found a decreased level of VCAN protein and mRNA in TOF.
However, it remains unclear for us about the relationship
between hypoxia and expression of VCAN. Further studies
should be proposed to unveil the potential pathophysiologic
implications of the decreased VCAN in TOF.
We compared our results to those of previous, analogous
studies [45–52]. The protein profile showed a distinct pattern,
and small parts of this pattern overlapped with the results
of those reports. We found human CHD to differ from the
traditional pulmonary artery banding animal model in its
pathophysiological process, time to progression, and molecu-
lar basis. Age, treatment, and other complications were found
to affect the proteomic profile. The heterogeneity of subjects
could explain why previous studies had different findings.
In addition, we also found that some unknown function
genes have potential in relation to cardiac hypertrophy, such
as Dnaja4 which plays a role in the development of coronary
microvascular remodeling in spontaneously hypertensive rat
(SHR) [53].
In conclusion, powerful comparative label-free proteomic
techniques were used to show the differential proteomic
profile during RV remodeling in CHD with chronic hypoxia
and long-term pressure overload. Results of the proteomic
analysis also indicated that the level of proteins related to
glycolysis increased and the level of proteins related to lipid
metabolism decreased. The ECM proteins showed a down-
regulated change under pathophysiological TOF conditions,
and this change was not detected in previous reports. These
findings indicate that TOF is a suitable model for the study of
RV pressure overload and hypoxia during cardiac remodeling
and that it may provide information on the metabolic
inflexibility and ECM remodeling that take place during the
early stages of RV remodeling in TOF. It may open newmeans
Fig. 4 – Representative immunohistochemical staining of PFKFB2, LCLAT1, LUM and VCAN in RV tissues from non-TOF (A, B, F, G, K, L, P, and Q), and TOF (C, D, H, I, M, N, R, and
S). The tissue sections were dewaxed in xylene and rehydrated in graded alcohols. After unmasking antigen and removing endogenous peroxidases, sections were incubated
for 12–14 h with antibodies against PFKFB2 (A, B, C, and D), LCLAT 1 (F, G, H, and I), LUM (K, L, M, and N) and VCAN (P, Q, R, and S), respectively, and detected with
HRP-conjugated secondary antibody and DAB substrate chromogen solution. Immunohistochemical analysis revealed that PFKFB2 and LCLAT1 were mainly expressed in the
cytoplasm of themyocardium (B, D, G, and I), LUM and VCANweremainly expressed in the extracellular region (L, N, Q, and S). A, C, F, H, K, M, P, and Rmagnification ×40, scale
bars: 50 μm; B, D, J, I, L, N, Q, and S magnification ×100, scale bars: 20 μm. Note that the stained patterns (E, G, O, and T) were correlated with Western blotting data.
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needed to analyze the proteomics of specific cell populations,
to identify the changes in the levels of less abundant proteins,
and to determine the effects of post-translational modifica-
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